Proteome analysis develops novel plasma proteins classifier in predicting the mortality of COVID-19

Abstract

COVID-19 has been a global concern for 3 years, however, consecutive plasma protein changes in the disease course are currently unclear. Setting the mortality within 28 days of admission as the main clinical outcome, plasma samples were collected from patients in discovery and independent validation groups at different time points during the disease course. The whole patients were divided into death and survival groups according to their clinical outcomes. Proteomics and pathway/network analyses were used to find the differentially expressed proteins and pathways. Then, we used machine learning to develop a protein classifier which can predict the clinical outcomes of the patients with COVID-19 and help identify the high-risk patients. Finally, a classifier including C-reactive protein, extracellular matrix protein 1, insulin-like growth factor-binding protein complex acid labile subunit, E3 ubiquitin-protein ligase HECW1 and phosphatidylcholine-sterol acyltransferase was determined. The prediction value of the model was verified with an independent patient cohort. This novel model can realize early prediction of 28-day mortality of patients with COVID-19, with the area under curve 0.88 in discovery group and 0.80 in validation group, superior to 4C mortality and E-CURB65 scores. In total, this work revealed a potential protein classifier which can assist in predicting the outcomes of COVID-19 patients and providing new diagnostic directions.

References

[1] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

[2] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574.

[3] Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453-455.

[4] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.

[5] Lu G, Ling Y, Jiang M, et al. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland. Front Med. 2023;17(4):758-767.

[6] Scaturro P, Stukalov A, Haas DA, et al. An orthogonal proteomic survey uncovers novel Zika virus host factors. Nature. 2018;561(7722):253-257.

[7] Shah PS, Link N, Jang GM, et al. Comparative flavivirus-host protein interaction mapping reveals mechanisms of dengue and Zika virus pathogenesis. Cell. 2018;175(7):1931-1945.e18.

[8] Nightingale K, Lin KM, Ravenhill BJ, et al. High-definition analysis of host protein stability during human cytomegalovirus infection reveals antiviral factors and viral evasion mechanisms. Cell Host Microbe. 2018;24(3):447-460.e11.

[9] Jean Beltran PM, Cook KC, Hashimoto Y, et al. Infection-induced peroxisome biogenesis is a metabolic strategy for herpesvirus replication. Cell Host Microbe. 2018;24(4):526-541.e7.

[10] Peters-Sengers H, Butler JM, Uhel F, et al. Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study. Intensive Care Med. 2022;48(1):92-102.

[11] Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182(1):59-72.e15.

[12] Captur G, Moon JC, Topriceanu CC, et al. Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. EBioMedicine. 2022;85:104293.

[13] Shu T, Ning W, Wu D, et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity. 2022;53(5):1108-22.e5.

[14] Wang Y, Zhu Q, Sun R, et al. Longitudinal proteomic investigation of COVID-19 vaccination. Protein Cell. 2023;14(9):668-682.

[15] Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ. 2020;370:m3339.

[16] Liu JL, Xu F, Zhou H, et al. Expanded CURB-65: a new score system predicts severity of community-acquired pneumonia with superior efficiency. Sci Rep. 2016;6:22911.

[17] Zhang Y, Cai X, Ge W, et al. Potential use of serum proteomics for monitoring COVID-19 progression to complement RT-PCR detection. J Proteome Res. 2022;21(1):90-100.

[18] Ge W, Liang X, Zhang F, et al. Computational optimization of spectral library size improves DIA-MS proteome coverage and applications to 15 tumors. J Proteome Res. 2021;20(12):5392-5401.

[19] Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods. 2020;17(1):41-44.

[20] Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.

[21] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D613.

[22] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.

[23] Guan WJ, Zhong NS. Clinical characteristics of Covid-19 in China. Reply. N Engl J Med. 2020;382(19):1861-1862.

[24] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.

[25] Yang X, Yang Q, Wang Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469-1472.

[26] Shen X, Wang P, Shen J, et al. Neurological manifestations of hospitalized patients with mild to moderate infection with SARS-CoV-2 Omicron variant in Shanghai, China. J Infect Public Health. 2023;16(2):155-162.

[27] Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet. 2022;399(10335):1618-1624.

[28] Li J, Song R, Yuan Z, et al. Protective effect of inactivated COVID-19 vaccines against progression of SARS-CoV-2 Omicron and Delta variant infections to pneumonia in Beijing, China, in 2022. Vaccines. 2022;10(8):1215.

[29] Ramlall V, Thangaraj PM, Meydan C, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020;26(10):1609-1615.

[30] Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22(2):77-84.

[31] Yan J, Horng T. Lipid metabolism in regulation of macrophage functions. Trends Cell Biol. 2020;30(12):979-989.

[32] Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233-247.

[33] Song JW, Lam SM, Fan X, et al. Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis. Cell Metab. 2020;32(2):188-202.e5.

[34] Ilias I, Diamantopoulos A, Botoula E, et al. Covid-19 and growth hormone/insulin-like growth factor 1: study in critically and non-critically ill patients. Front Endocrinol (Lausanne). 2021;12:644055.

[35] Gong B, Huang L, He Y, et al. A genetic variant in IL-6 lowering its expression is protective for critical patients with COVID-19. Signal Transduct Target Ther. 2022;7(1):112.

[36] Milenkovic M, Hadzibegovic A, Kovac M, et al. D-dimer, CRP, PCT, and IL-6 levels at admission to ICU can predict in-hospital mortality in patients with COVID-19 pneumonia. Oxid Med Cell Longev. 2022;2022:8997709.

[37] Saridaki M, Metallidis S, Grigoropoulou S, et al. Integration of heparin-binding protein and interleukin-6 in the early prediction of respiratory failure and mortality in pneumonia by SARS-CoV-2 (COVID-19). Eur J Clin Microbiol Infect Dis. 2021;40(7):1405-1412.

[38] Oblitas CM, Galeano-Valle F, Cuenca-Carvajal C, et al. Evaluation of simple laboratory parameters in SARS-CoV-2 infection: the role of ratios. Infect Dis (Lond). 2022;54(12):924-933.

[39] Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.

[40] Daulny A, Tansey WP. Damage control: DNA repair, transcription, and the ubiquitin-proteasome system. DNA Repair (Amst). 2009;8(4):444-448.

[41] Yadav D, Lee JY, Puranik N, et al. Modulating the ubiquitin-proteasome system: a therapeutic strategy for autoimmune diseases. Cell. 2022;11(7):1093.

[42] Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 2020;19(1):146.

[43] Zhao M, Zhang M, Yang Z, Zhou Z, Huang J, Zhao B. Role of E3 ubiquitin ligases and deubiquitinating enzymes in SARS-CoV-2 infection. Front Cell Infect Microbiol. 2023;13:1217383.

[44] Wang C, Dong K, Wang Y, et al. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma. BMC Cancer. 2021;21(1):890.

[45] Kosek AB, Durbin D, Jonas A. Binding affinity and reactivity of lecithin cholesterol acyltransferase with native lipoproteins. Biochem Biophys Res Commun. 1999;258(3):548-551.

[46] Begue F, Chemello K, Veeren B, et al. Plasma apolipoprotein concentrations are highly altered in severe intensive care unit COVID-19 patients: preliminary results from the LIPICOR cohort study. Int J Mol Sci. 2023;24(5):4605.

[47] Stadler JT, Mangge H, Rani A, et al. Low HDL cholesterol efflux capacity indicates a fatal course of COVID-19. Antioxidants (Basel). 2022;11(10):1858.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.